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This Focus article highlights three unrelated studies, the ﬁrst
exploring the role of gene polymorphisms in the risk of spontane-
ous bacterial peritonitis (SBP) (‘‘Nature’’), the inhibitory activity
of a grapefruit ﬂavonoid on hepatitis C virus (HCV) replication
(‘‘Natural’’), and the role of multipotent stromal cells in correct-
ing defects in a mouse fatty liver disease model (‘‘NAFLD’’).
In the ﬁrst study by Nischalke and colleagues, sequence vari-
ants in the gene encoding for the membrane receptor Toll-like
receptor 2 were linked to an increased prevalence of SBP among
cirrhotics who had ascites. TLR2 is a well characterized cell mem-
brane pattern recognition receptor that is a vital component of
the innate immune system, whose primary role is to recognize
gram positive bacterial patterns and elicit protective signaling
cascades [1,2]. Thus, the genetic variants that reduce the activity
of TLR2 could amplify the risk of infection from gut bacteria
among cirrhotics with ascites, who are already at heightened risk
for infections. The two polymorphism conferring increased sus-
ceptibility, the 16934 TT and TLR2 GT microsatellite variants
may reduce the activity of the receptor such that there is
decreased release of inﬂammatory cytokines in these susceptible
patients in response to gut bacteria. The ﬁndings are reminiscent
of a recent study highlighting how variants of the TLR4 gene,
which signals in response to gram negative bacterial patterns,
affects the progression rate of ﬁbrosis in patients with HCV [3].
The TLR2 ﬁndings represent another example of the progres-
sive assimilation of host genetic variants into our classiﬁcation
of disease risk that will subtly, but inevitably, change the way
we practice medicine. And while the ﬁndings make sense based
on our knowledge of TLR2 function, this study lacks a speciﬁc
demonstration that the susceptibility variants negatively affect
the function of cells directly responsible for preventing SBP. Spe-
ciﬁcally, in which cells are the TLR2 variants failing to respond
adequately to gram positive bacteria – gut, peritoneal or hepatic
macrophages, other resident cells of liver, or circulating immune
cells? Are peritoneal macrophages from ascites in patients with
the variants less responsive to bacterial antigens? Also, what is
the mechanism by which these variants affect signaling in the
responsible cells? Increasingly, experts demand that disease sus-
ceptibility variants be linked to a clear underlying mechanism,
and while one is suggested by studies of TLR2 in other tissuesJournal of Hepatology 20
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hopefully ﬁll. Still, if the ﬁndings were replicated in multiple
cohorts, the identiﬁcation of susceptibility variants in patients
with ascites might prompt the testing of primary prophylactic
antibiotics in high-risk patients in a prospective randomized trial.
Moreover, since additional variants in the nucleotide binding
oligomerization domain (NOD2) gene conferred an independent,
additive risk of SBP in this study, one could envision an aggregate
score that could predict the risk of this infection, and deﬁne those
who would beneﬁt from prophylactic therapies.
In the article by Goldwasser et al., the activity of a grapefruit
ﬂavonoid, naringenin, has been shown to interfere with HCV
assembly in the widely used viral replication system of Huh
7.5.1 cells. ‘Flavonoids’ refer to a class of plant-derived polyphe-
nolic yellow pigments containing ketones, which are commonly
found in the human diet. Their remarkable breadth of biologic
activity includes anti-cancer, anti-oxidant, and anti-bacterial
properties, among many others. Flavonoids’ appeal as a natural
therapy for disease is well known, but less appreciated is that
approximately 25% of all FDA-approved drugs have originated
from botanicals, and the global market for botanical and plant
derived drugs is more than $20 billion and growing.
In the case of naringenin, the compound has already been
shown to modestly lower LDL cholesterol in human subjects [5]
through a number of effects on lipid homeostasis, and has anti-
cancer, anti-oxidant, and anti-diabetogenic activities in a range
of animal models. The Goldwasser study in HCV was prompted
in part by the recognition that viral replication is dependent on
the lipid machinery of susceptible cells [6]. Their experiments
carefully and systematically link an antiviral effect of naringenin
to stimulation of PPARa, a key nuclear receptor that regulates
lipid homeostasis, blocking VLDL production and signiﬁcantly
reducing ApoB secretion without affecting cell viability or leading
to lipid accumulation. The result is a blockade to the assembly of
infectious particles, but without an effect on viral replication per
se. While the activity of this compound in reducing HCV RNA
secretion was relatively modest (1.4 log) compared to a recently
approved protease inhibitor, VX-950 (telaprevir) (4.7 log) [7], the
safety of naringenin and its potential synergy with existing ther-
apies make this compound especially appealing. Moreover,
because the drug has already been safely tested in humans, the
path toward its inclusion into multi-drug regimens for HCV
seems straightforward, provided there is a willing commercial
sponsor that can support its development. Whether naringenin
can ﬁnd such a suitor in the already crowded landscape of HCV
agents may partly determine its market viability. Regardless of11 vol. 55 j 953–954
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this fact, the ﬁndings underscore the vast potential of natural
compounds to emerge as tomorrow’s therapies.
The third study by Ezquer et al., adds additional evidence,
albeit preliminary, of the potential power of stem cells to treat
liver disease. A growing number of reports have used a range of
bone-marrow derived and ‘stem’ cells as potential therapies for
liver disease in both animal models and human trials (reviewed
in [8]). A wide number of tissue sources, cell characterization,
mode of administration, and endpoints of efﬁcacy have been uti-
lized, which make direct comparisons difﬁcult. However, some
general principles help deﬁne whether a study is meaningful,
including the requirements to: (1) meticulously characterize
the phenotype and purity of administered cells; this is especially
critical to avoid the risk of sowing a malignancy if undifferenti-
ated stem cells are administered; (2) track the longevity and sites
of administered cells; (3) clarify whether therapeutic effects are a
direct result of the administrated cells or due to indirect effects
on host effector cells; (4) deﬁne speciﬁc mechanism and media-
tors underlying a therapeutic effect; (5) establish the safety and
durability of a response; and (6) deﬁne the types and stages of
disease(s) that will beneﬁt from potential therapies.
In the context of these requirements, the Ezquer study has
some strengths, but also some notable deﬁciencies. Perhaps most
appealing is their use of cell therapy to correct histologic abnor-
malities associated with a high fat diet in mice, rather than to
either rescue liver function or reverse ﬁbrosis as in prior studies.
The authors treated mice that had been on a high fat diet for
33 weeks with two doses, 4 weeks apart, of 5  105 ‘multipotent
stromal cells’ (MSCs) that had been harvested and expanded
ex vivo (deﬁned by ﬂow cytometry using a panel of cell surface
markers), followed by sacriﬁce of the mice at 50 weeks. MSCs
were also labeled with green ﬂuorescent protein to track their
fate in situ.
The results of MSC administration were striking but largely
unexplained. MSC-treated mice had reduced transaminases,
hepatomegaly, and ﬁbrosis, and had attenuated steatosis com-
pared to high fat diet-fed mice that were untreated. At the time
of sacriﬁce 17 weeks after their administration, donor cells were
only detectable in obese but not in control mice, distributed
amongst liver, bone marrow, heart, and kidney, and visible as sin-
gle cells, primarily in the portal areas. There was no deﬁnitive
evidence of cell fusion with hepatocytes since the GFP positive
cells did not express albumin.
The ﬁndings are intriguing but not wholly satisfying, as no
underlying mechanisms were offered and it is unclear if the
result is direct or indirect via recruitment of host cells. In con-
trast, a recent study carefully distinguished these two possibili-954 Journal of Hepatology 201ties in a murine model of CCl4-induced injury and ﬁbrosis,
demonstrating that only differentiated macrophages had a salu-
tary effect, whereas whole bone marrow exacerbated the disease
[9]. Additionally, in the Ezquer study, the preferential engraft-
ment of cells in obese but not normal livers is also quite interest-
ing but not explored.
In summary, this study using a partially characterized stromal
cell type raises the possibility that defects associated with fatty
liver may be correctable, at least transiently, by cell based ther-
apy. Continued reﬁnement of the cell type(s) that confer beneﬁt,
use of a larger number of controls, application to other fatty liver
disease models, and elucidation of speciﬁc mechanism(s) that
account for these remarkable ﬁndings could bring real value to
this approach, but much work remains to be done.Conﬂict of interest
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